Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-4208 pharmacokinetics in severe renal impairment
NCT02578082Phase 1Completed
- Sponsor
- Mylan
- Start
- Dec 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of revefenacin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Mylan. Primary endpoint: Maximum observed plasma concentration. Started Dec 2015; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02578082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578082.